全文获取类型
收费全文 | 44173篇 |
免费 | 3342篇 |
国内免费 | 178篇 |
专业分类
耳鼻咽喉 | 332篇 |
儿科学 | 1240篇 |
妇产科学 | 936篇 |
基础医学 | 5723篇 |
口腔科学 | 746篇 |
临床医学 | 4532篇 |
内科学 | 9794篇 |
皮肤病学 | 647篇 |
神经病学 | 4441篇 |
特种医学 | 1457篇 |
外国民族医学 | 1篇 |
外科学 | 6182篇 |
综合类 | 729篇 |
一般理论 | 32篇 |
预防医学 | 3884篇 |
眼科学 | 784篇 |
药学 | 3145篇 |
1篇 | |
中国医学 | 55篇 |
肿瘤学 | 3032篇 |
出版年
2023年 | 236篇 |
2022年 | 306篇 |
2021年 | 807篇 |
2020年 | 554篇 |
2019年 | 802篇 |
2018年 | 929篇 |
2017年 | 735篇 |
2016年 | 755篇 |
2015年 | 926篇 |
2014年 | 1317篇 |
2013年 | 1862篇 |
2012年 | 2783篇 |
2011年 | 3107篇 |
2010年 | 1700篇 |
2009年 | 1553篇 |
2008年 | 2621篇 |
2007年 | 2877篇 |
2006年 | 2742篇 |
2005年 | 2821篇 |
2004年 | 2605篇 |
2003年 | 2480篇 |
2002年 | 2284篇 |
2001年 | 628篇 |
2000年 | 529篇 |
1999年 | 641篇 |
1998年 | 541篇 |
1997年 | 421篇 |
1996年 | 418篇 |
1995年 | 359篇 |
1994年 | 316篇 |
1993年 | 336篇 |
1992年 | 433篇 |
1991年 | 415篇 |
1990年 | 388篇 |
1989年 | 317篇 |
1988年 | 314篇 |
1987年 | 286篇 |
1986年 | 258篇 |
1985年 | 308篇 |
1984年 | 358篇 |
1983年 | 291篇 |
1982年 | 302篇 |
1981年 | 297篇 |
1980年 | 274篇 |
1979年 | 196篇 |
1978年 | 190篇 |
1977年 | 175篇 |
1976年 | 156篇 |
1974年 | 160篇 |
1973年 | 123篇 |
排序方式: 共有10000条查询结果,搜索用时 279 毫秒
51.
52.
Steven J Lobritto Philip Rosenthal Rene Bouw Mimi Leung Paul Snell Richard D Mamelok 《Liver transplantation》2007,13(11):1570-1575
There are few pharmacokinetic data for mycophenolate mofetil (MMF) when used in combination with cyclosporine (CsA) in pediatric liver transplant recipients. The aim of this study was to assess the pharmacokinetics of MMF in stable pediatric liver transplant patients and estimate the dose of MMF required to provide a mycophenolic acid (MPA) exposure similar to that observed in adult liver transplant recipients receiving the recommended dose of MMF (target area under the plasma concentration-time curve from 0 to 12 hours [AUC(0-12)] for MPA of 29 mug.hour/mL in the immediate posttransplantation period and 58 microg x hour/mL after 6 months). A 12-hour pharmacokinetic profile was collected for 8 pediatric patients (mean age 20.9 months) on stable doses of MMF and CsA who had received a liver transplant > or = 6 months prior to entry and who had started on MMF within 2 weeks of transplantation. Mean MMF dosage was 285 mg/m(2) (range, 200-424 mg/m(2)). Of 8 patients, 7 had a MPA AUC(0-12) (range, 11.0-37.2 microg x hour/mL) well below the target. One patient had an AUC(0-12) > or = 58 microg x hour/mL but was considered an outlier and was excluded from analyses. Mean MPA AUC(0-12) and maximum plasma concentration values were 22.7 +/- 10.5 microg x hour/mL and 7.23 +/- 3.27 microg/mL, respectively; values normalized to 600 mg/m(2) (the approved pediatric dose in renal transplantation) were 47.0 +/- 21.8 microg x hour/mL and 14.5 +/- 4.21 microg/mL. In conclusion, assuming that MPA exhibits linear pharmacokinetics, when used in combination with CsA, a MMF dose of 740 mg/m(2) twice daily would be recommended in pediatric liver transplant recipients to achieve MPA exposures similar to those observed in adult liver transplant recipients. This finding should be confirmed by a prospective trial. 相似文献
53.
Philip F. Giampietro MD PhD Margaret G. E. Peterson PhD Robert Schneider MD Jessica G. Davis MD Stephen W. Burke MD Oheneba Boachie-Adjei MD Charles M. Mueller PhD RD Cathleen L. Raggio MD 《HSS journal》2007,3(1):89-92
Reduced bone mineral density (BMD) was sporadically reported in patients with Marfan syndrome. This may or may not place the
Marfan patient at increased risk for bone fracture. In comparing the BMDs of our patients with those reported in the literature,
it seemed that agreement between values, and hence the degree of osteoporosis or osteopenia reported, was dependent on the
instrumentation used. The objective of this study was to statistically assess this impression. Bone mineral density measurements
from our previously published study of 30 adults with Marfan syndrome performed on a Lunar DPXL machine were compared with
studies published between 1993–2000 measured using either Lunar or Hologic bone densitometry instruments. The differences
of our measurements compared with those made on other Lunar machines were not statistically significant, but did differ significantly
with published results from Hologic machines (P < 0.001). Before progress can be made in the assessment of BMD and fracture risk in Marfan patients and in the evidence-based
orthopedic management of these patients, standardization of instrumental bone density determinations will be required along
with considerations of height, obesity, age, and sex. 相似文献
54.
Hung-Fat Tse Sukumaran Thambar Yok-Lam Kwong Philip Rowlings Greg Bellamy Jane McCrohon Paul Thomas Bruce Bastian John K F Chan Gladys Lo Chi-Lai Ho Wing-Sze Chan Raymond Y Kwong Anthony Parker Thomas H Hauser Jenny Chan Daniel Y T Fong Chu-Pak Lau 《European heart journal》2007,28(24):2998-3005
AIMS: Experimental studies have demonstrated that bone marrow (BM) cells can induce angiogenesis in ischaemic myocardium. Recently, several non-randomized pilot studies have also suggested that direct BM cells implantation appears to be feasible and safe in patients with severe coronary artery diseases (CAD). METHODS AND RESULTS: We performed a randomized, blinded, and placebo-controlled trial in 28 CAD patients. After BM harvesting, we assigned patients to receive low dose (1 x 10(6) cells/0.1 mL, n = 9), high dose (2 x 10(6) cells/0.1 mL, n = 10) autologous BM cells or control (0.1 mL autologous plasma/injection, n = 9) catheter-based direct endomyocardial injection as guided by electromechanical mapping. Our primary endpoint was the increase in exercise treadmill time and our secondary endpoints were changes in Canadian Cardiovascular Society (CCS) and New York Heart Association (NYHA) class, and myocardial perfusion and left ventricular ejection fraction (LVEF) assessed by single-photon emission computed tomography and magnetic resonance imaging, respectively. A total 422 injections (mean 14.6 +/- 0.7 per patient) were successfully performed at 41 targeted ischaemic regions without any acute complication. Baseline exercise treadmill time was 439 +/- 182 s in controls and 393 +/- 136 s in BM-treated patients, and changed after 6 months to 383 +/- 223s and 464 +/- 196 s [BM treatment effect +0.43 log seconds (+53%), 95% CI 0.11-0.74, P = 0.014]. Compared with placebo injection, BM implantation was associated with a significant increase in LVEF (BM treatment effect +5.4%, 95% CI 0.4-10.3, P = 0.044) and a lower NYHA class (odds ratio for treatment effect 0.12, 95% CI 0.02-0.73, P = 0.021) after 6 months, but CCS reduced similarly in both groups. We observed no acute or long-term complications, including ventricular arrhythmia, myocardial damage, or development of intramyocardial tumour or calcification associated with BM implantation. CONCLUSION: Direct endomyocardial implantation of autologous BM cells significantly improved exercise time, LVEF, and NYHA functional class in patients with severe CAD who failed conventional therapy. 相似文献
55.
Philip E Benson C W Ian Douglas Michael V Martin 《American journal of orthodontics and dentofacial orthopedics》2004,126(3):325-330
The objective of this study was to investigate the effect of fluoridated elastomeric ligatures on the microbiology of local dental plaque in vivo. This randomized, prospective, longitudinal, clinical trial had a split-mouth crossover design. The subjects were 30 patients at the beginning of their treatment with fixed orthodontic appliances in the orthodontic departments of the Liverpool and the Sheffield dental hospitals in the United Kingdom. The study consisted of 2 experimental periods of 6 weeks with a washout period between. Fluoridated elastomers were randomly allocated at the first visit to be placed around brackets on tooth numbers 12, 11, 33 or 22, 21, 43. Nonfluoridated elastomers were placed on the contralateral teeth. Standard nonantibacterial fluoridated toothpaste and mouthwash were supplied. After 6 weeks (visit 2), the elastomers were removed, placed in transport media, and plated on agar within 2 hours. Nonfluoridated elastomers were placed on all brackets for 1 visit to allow for a washout period. At visit 3, fluoridated elastomers were placed on the teeth contralateral to those that received them at visit 1. At visit 4, the procedures at visit 2 were repeated. Samples were collected on visits 2 and 4. A logistic regression was performed, with the presence or absence of streptococcal or anaerobic growth as the dependent variable. A mixed-effects analysis of variance was carried out with the percentage of streptococcal or anaerobic bacterial count as the dependent variable. The only significant independent variables were the subject variable (P =<.001) for the percentage of streptococcal and anaerobic bacterial count and the visit variable for the percentage of streptococcal count (P =<.001). The use of fluoridated or nonfluoridated elastomers was not significant for percentage of either streptococcal (P =.288) or anaerobic count (P =.230). Fluoridated elastomers are not effective at reducing local streptococcal or anaerobic bacterial growth after a clinically relevant time in the mouth. 相似文献
56.
57.
58.
Gahan J Pandina Robert Bilder Philip D Harvey Richard S E Keefe Michael G Aman Georges Gharabawi 《Neuropsychopharmacology》2007,62(3):226-234
BACKGROUND: Effects of risperidone on cognitive function in children with disruptive behavior disorders (DBDs) and subaverage intelligence quotient (IQ) were assessed. METHODS: Data from two 6-week, double-blind, placebo-controlled studies (n = 228) were combined, as were three 1-year, open-label studies (n = 688). Patients with DBDs and subaverage IQ, 5 to14 years, received placebo or risperidone .02 to .06 mg/kg/day. Cognitive measures included the Continuous Performance Task (CPT) and Verbal Learning Test for Children (VLT-C). Efficacy was assessed using the Nisonger Child Behavior Rating Form (NCBRF). Adverse events were collected via spontaneous report; sedation was assessed using visual analog scale. RESULTS: Improvements on the NCBRF Conduct Problem subscale were significantly greater for risperidone- versus placebo-treated patients (-15.8 vs. -6.4, p < .0001) in short-term studies; significant reductions were observed in long-term studies (-16.3, p < .0001). No overall decline and some significant improvement in attention (CPT) and memory (VLT-C) were noted regardless of treatment in short-term studies. VLT-C improved significantly (p < .0001) for both groups, with no difference between treatment groups. Improvements in memory (VLT-C) and attention (CPT) were noted in long-term studies. Somnolence/sedation did not affect cognitive function. CONCLUSIONS: Cognitive function was not altered by risperidone in short-term studies and was maintained or improved with one year of treatment in children with DBDs and subaverage IQ, potentially representing age-appropriate gains. 相似文献
59.
60.
Yue Chen Deborah L Levy Summer Sheremata Philip S Holzman 《Neuropsychopharmacology》2004,55(8):834-841
BACKGROUND: Visual motion processing is compromised in schizophrenia, as shown in deficient velocity discrimination. Processing of motion signals comprises progressive stages along the geniculate-striate-extrastriate-cortex pathway. Based on neurophysiologic and brain lesion studies, a velocity discrimination deficit can implicate early-stage motion processing if it is contrast-dependent or late-stage motion processing if it is contrast-independent. METHODS: To determine which stage underlies the deficient velocity discrimination in schizophrenia, we examined the effects of visual contrast on velocity discrimination. We measured velocity discrimination thresholds in schizophrenia patients (n = 34) and normal control subjects (n = 17) at both low and high contrasts, using each subject's contrast detection threshold to equate contrast levels. RESULTS: Schizophrenia patients showed poor velocity discrimination that improved little with high contrast, whereas normal control subjects showed enhanced velocity discrimination with increased contrast. CONCLUSIONS: The finding that the velocity discrimination deficit in schizophrenia is independent of contrast modulation implicates the later, rather than the earlier, stages of motion processing, which is mediated in the extrastriate cortex. 相似文献